<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01146574</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-011-REN-001</org_study_id>
    <nct_id>NCT01146574</nct_id>
  </id_info>
  <brief_title>A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.</brief_title>
  <official_title>A Phase 2a, Multi-center, Randomized, Single Dose, Double-blind, Placebo-controlled Followed by a Multiple-dose, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Efficacy, Tolerability, and Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease (ESRD) on Hemodialysis (HD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acceleron Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first study in hemodialysis subjects with anemia to evaluate the
      pharmacokinetics, safety, efficacy, tolerability, and pharmacodynamics of sotatercept
      (ACE-011)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1:

      Approximately 8 subjects will be randomized to receive either a single 0.1 mg/kg subcutaneous
      dose of sotatercept or matching placebo in a 3:1 ratio

      Part 2:

      Approximately 8 subjects will be randomized to each of the 3 sequential dose groups (0.3mg/kg
      or 0.5mg/kg or 0.7 mg/kg) with a 3:1 ratio of sotatercept or placebo (6 subjects in the
      sotatercept arm and 2 in the placebo arm). A total of 24-36 subjects may be randomized in the
      3 dose groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2010</start_date>
  <completion_date type="Actual">March 7, 2016</completion_date>
  <primary_completion_date type="Actual">March 7, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK-Observed maximum Concentration (Cmax)</measure>
    <time_frame>Up to 309 days</time_frame>
    <description>PK-Observed maximum Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-Time to maximum concentration (Tmax)</measure>
    <time_frame>Up to 309 days</time_frame>
    <description>PK-Time to maximum concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-Area under the concentration-time curve over the 28 day dosing interval (AUC 28d)</measure>
    <time_frame>Up to 309 days</time_frame>
    <description>PK-Area under the concentration-time curve over the 28 day dosing interval (AUC 28d)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK-Terminal half-life (T1/2,z)</measure>
    <time_frame>Up to 309 days</time_frame>
    <description>PK-Terminal half-life (T1/2,z)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>Up to 309 days</time_frame>
    <description>Number of participants with Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Hb &gt; 12g/dL</measure>
    <time_frame>Up to 309 days</time_frame>
    <description>Proportion of subjects with Hb &gt; 12g/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with rise in Hb &gt; 2 g/dL during a 4 week period</measure>
    <time_frame>Up to 309 days</time_frame>
    <description>Proportion of subjects with rise in Hb &gt; 2 g/dL during a 4 week period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of clinically significant changes in laboratory parameters from baseline</measure>
    <time_frame>Up to 309 days</time_frame>
    <description>Frequency of clinically significant changes in laboratory parameters from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure changes from baseline</measure>
    <time_frame>Up to 309 days</time_frame>
    <description>Blood pressure changes from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects that are able to achieve an absolute Hb concentration of &gt; 10 g/dL</measure>
    <time_frame>Up to 309 days</time_frame>
    <description>Proportion of subjects that are able to achieve an absolute Hb concentration of &gt; 10 g/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach target Hb concentration (&gt; 10 g/dL) and target increase in Hb (≥ 1g/dL)</measure>
    <time_frame>Up to 309 days</time_frame>
    <description>Time to reach target Hb concentration (&gt; 10 g/dL) and target increase in Hb (≥ 1g/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects rescued and length of time to rescue therapy</measure>
    <time_frame>Up to 309 days</time_frame>
    <description>Proportion of subjects rescued and length of time to rescue therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Follicle Stimulating Hormone (FSH) and Sex Steroid Concentrations</measure>
    <time_frame>Up to 309 days</time_frame>
    <description>Changes in Follicle Stimulating Hormone and Sex Steroid Concentrations</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>0.1mg/kg Sotatercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 8 subjects will be randomized to receive either a single 0.1 mg/kg subcutaneous dose of sotatercept or matching placebo in a 3:1 ratio</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3mg/kg Sotatercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Group 1: 0.3 mg/kg sotatercept subcutaneous every 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5mg/kg Sotatercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Group 2: 0.5 mg/kg sotatercept subcutaneous every 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.7mg/kg Sotatercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Group 3: 0.7 mg/kg sotatercept subcutaneous every 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The Placebo to Sotatercept ratio is 1:3 meaning for every 1 patient that receives Placebo, 3 patients will receive Sotatercept.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sotatercept</intervention_name>
    <description>Part 1: Sotatercept single dose 0.1mg/kg subcutaneous Part 2: Sotatercept starting dose groups of 0.3mg/kg, 0.5mg/kg or 0.7 mg/kg in a sequential design, dosed subcutaneously every 28 days for up to 8 doses</description>
    <arm_group_label>0.1mg/kg Sotatercept</arm_group_label>
    <arm_group_label>0.3mg/kg Sotatercept</arm_group_label>
    <arm_group_label>0.5mg/kg Sotatercept</arm_group_label>
    <arm_group_label>0.7mg/kg Sotatercept</arm_group_label>
    <other_name>ACE-011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females ≥18 years of age.

          -  Subjects on hemodialysis for at least 12 weeks before screening

          -  Subjects on a stable dose of Erythrocyte Stimulating Agents product to maintain
             Hemoglobin (Hb) for at least 6 weeks prior to screening.

          -  3 consecutive pre-dialysis Hb concentrations with a mean ≥10 to ≤ 12 g/dL (≥100 to
             ≤120 g/L) at screening and one pre-dialysis Hb concentration ≥8 to &lt; 10 g/dL (≥ 80 to
             &lt; 100 g/L) before randomization.

          -  Adequate iron status defined as serum transferrin saturation ≥ 20% before
             randomization.

        Exclusion Criteria:

          -  Non renal causes of anemia.

          -  Subjects on peritoneal dialysis.

          -  Systemic hematological disease

          -  High sensitivity C-reactive protein &gt;50mg/L at screening.

          -  Alanine transaminase (ALT) or aspartate transaminase (AST) laboratory values &gt; 2 times
             the upper limit of normal (ULN) at screening.

          -  Uncontrolled diabetes mellitus (HbA1c &gt; 9) at screening.

          -  Uncontrolled hypertension.

          -  Red Blood Count (RBC) transfusions within 8 weeks prior to screening.

          -  Active serious infection or history of recurrent serious infection likely to recur
             during the study

          -  History of severe allergic or anaphylactic reactions or hypersensitivity to
             recombinant proteins or excipients in the investigational product or to the iron
             products needed to normalize iron levels for subjects.

          -  Subjects that received treatment with another investigational drug or device within 28
             days prior to Day 1

          -  Pregnant or lactating females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William T Smith, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North American Research Institute</name>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91702-3439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Glendale Dialysis</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Institute of Renal Research</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrology Specialist Medical Group</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pines Clinical Research Inc.</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresenius Medical Care North America MI</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrology and Hypertension Associates, LTD</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kidney Specialists of Southen Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brookview Hill Research Associates, LLC</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Systems</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Clinical Research Center</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrology Associates, PC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corva Kidney Center Webster</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beechnut Dialysis Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miracle Medical Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gessner Dialysis Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Nephrology Associates, PC</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia at University Ave.</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2010</study_first_submitted>
  <study_first_submitted_qc>June 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2010</study_first_posted>
  <disposition_first_submitted>March 7, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>March 7, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 8, 2017</disposition_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>End-Stage Renal Disease</keyword>
  <keyword>Anemia</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Renal Anemia</keyword>
  <keyword>ESRD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

